Biogen’s Alzheimer’s Drug Flop Could Wipe Out a Third of Value

(Bloomberg) -- Biogen Inc. and partner Eisai Co’s decision to stop late-stage studies of their Alzheimer’s disease drug aducanumab could wipe out about 30 percent of the drugmaker’s value, accordin...